Noxopharm
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
159 Ridgecrop Dr Ste 71, Castle Hill, Ne...Phone Number
+61 291442223Website
www.noxopharm.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Noxopharm
Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation, as well as enhancing mRNA vaccines. The company utilizes two technology platforms, Chroma and Sofra, to create a pipeline of proprietary drugs aimed at addressing oncology and autoimmune diseases. Their clinical drug candidate, Veyonda, is currently undergoing trials to improve cancer treatment in conjunction with immunotherapy. Noxopharm is committed to tackling significant medical challenges through innovative research and development approaches.Explore more
Noxopharm Org Chart
SB
Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Noxopharm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Noxopharm launches new products
Noxopharm, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Noxopharm is spiking on competitors!
Funding: Get notified immidiatlly once Noxopharm has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Noxopharm has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Noxopharm
Earning: See what the market has to say on Noxopharm recently announced quarterly report
Click to see if Noxopharm had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Noxopharm as Masked Content
Find 2 more new buyers
Compare Similar Companies to Noxopharm
Compare insights from companies similar to Noxopharm, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Noxopharm is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Noxopharm is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Noxopharm.
Noxopharm financials insights
Gather financial insights about Noxopharm, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Debt
$15M
2020
Share Placement
$8.1M
Noxopharm Tech Stack
A closer look at the technologies used by Noxopharm
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
Lateral Move
Executive Move
As previously announced, Graham Kelly, Chief Executive Officer, has transitioned to the role of Non-Executive Director & Consultant.
Promotion
Executive Move
Lateral Move
Executive Move
Noxopharm News & Media
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Proactive news headlines including Kinetiko Energy, Noxopharm, Australian Strategic Materials and Aurumin Ltd
Sydney, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Proactive news headlines including Westar Resources, KGL Resources, Noxopharm and Eclipse Metals
Sydney, June 14, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
SYDNEY--(BUSINESS WIRE)-- #Veyonda--Australian biotech company Noxopharm has announced the FDA granted Orphan Drug Designation (ODD) to Veyonda®.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Noxopharm
Sign Up For FreeTo access detailed company insights
Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation, as well as enhancing mRNA vaccines. The company utilizes two technology platforms, Chroma and Sofra, to create a pipeline of proprietary drugs aimed at addressing oncology and autoimmune diseases. Their c... Read More
